---
search:
  boost: 3
---

# Antiparasitics

This is a subcategory of Topical Agents.

## Decision Tree

[Topical - Antiparasitics - NP - Eurax, Malathion, Sklice, Spinosad](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUOEJOTERENjUwMzJVOFI1Q0FUTFZKN1pEMyQlQCNjPTEkJUAjdD1n){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                       | Generic Name | Quantity | Time (Days) |
|:--------------------------------|:-------------|:--------:|:-----------:|
| Natroba <sup>BvG ==(Process by NDC)==</sup>          |              |          |             |
| Permethrin                      |              |          |             |
| Piperonyl Butoxide / Pyrethrins |              |          |             |

### Non-Preferred

| Non-Preferred                                                                           | Generic Name | Quantity | Time (Days) |
|:----------------------------------------------------------------------------------------|:-------------|:--------:|:-----------:|
| Eurax                                                                                   |              |          |             |
| Ivermectin Lot                                                                          |              |          |             |
| Malathion                                                                               |              |          |             |
| <span title = "Brand Preferred: Natroba">Spinosad</span> <sup>Brand Preferred</sup> |              |          |             |

## Authorizations 

**Length of Authorizations**: 14 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response to at least **14 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701+UPDL+Criteria+_v1_FINAL.approved.pdf#page=103){ :target="_blank" rel="noopener" }

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230701_UPDL_FINAL_ODM.approved.v2.pdf#page=32){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
